



ASX Release

Avexa appoints US-based Non-Executive Director

17 April, 2008

Avexa Ltd (AVX) announced today that it has appointed Nathan Drona a Non-Executive Director of the Company.

Nathan Drona is an experienced international investment banker in the life sciences industry and has successfully advised numerous companies in the US, Europe, and Australia in mergers and acquisitions strategy. Most recently, he was a managing director for Challiss, an independent M&A advisory firm based in New York.

Mr Cooper commented "As the newly appointed Chairman of the Company, I am delighted to welcome Nathan to the Board. Based in the US, his strong capital markets background, expertise in licensing and M&A, and key existing relationships in the institutional investment community will be of significant benefit to the Board of Avexa."

Mr Drona added "I am delighted for the opportunity to the join the board of Avexa during this exciting time in its continued development. With Avexa's Phase III trial for apricitabine underway and as international interest in the company continues to grow, I think the company has tremendous potential for success."

For more information:

Dr. Julian Chick
Chief Executive Officer
+61 3 9208 4300

Mr Rod North
Bourse Communications
+ 61 (03) 9510-8309

www.avexa.com.au

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects including its HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC), an anti-HIV drug which has successfully completed the 24 week dosing of its Phase 2b trial and has recently initiated Phase 3 trials. Avexa has entered into a collaboration with TargetDrug in China to identify new CCR5 inhibitors for the treatment of HIV.